Cocrystal Pharma Inc

COCP

Company Profile

  • Business description

    Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

  • Contact

    19805 North Creek Parkway
    BothellWA98011
    USA

    T: +1 877 262-7123

    E: [email protected]

    https://www.cocrystalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    10

Stocks News & Analysis

stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.
stocks

TSMC earnings: Refining guidance and expansion plans amid strong AI demand

We maintain our fair value estimate for TSMC stock.
stocks

Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio

Trying to make sense of a share caught up in irrational exuberance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,168.7033.000.36%
CAC 408,425.130.000.00%
DAX 4024,702.24547.772.27%
Dow JONES (US)49,447.43868.711.79%
FTSE 10010,667.6377.640.73%
HKSE26,160.33233.93-0.89%
NASDAQ24,468.48365.781.52%
Nikkei 22558,475.901,042.44-1.75%
NZX 50 Index12,905.67160.39-1.23%
S&P 5007,126.0684.781.20%
S&P/ASX 2008,946.9036.800.41%
SSE Composite Index4,051.434.12-0.10%

Market Movers